A Phase 2 interventional study of Ayahuasca and Esketamine in Major Depression Severe, sponsored by University of Sao Paulo. Completed at 1 site in Brazil. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-12-29.
Sponsored by University of Sao Paulo · Phase 2, Interventional, and Treatment
Double-blind, randomized trial comparing 4 weekly doses of oral ayahuasca and esketamine in patients with major depression.
University of Sao Paulo is the lead sponsor of 1,005 studies on the registry; 90 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
- Clinical diagnosis of depressive disorder
Exclusion Criteria:
- Presence of psychiatric and other medical comorbidities
oral ayahuasca
Drug: Ayahuasca · Drug: Esketamine
oral esketamine
Drug: Ayahuasca · Drug: Esketamine
Oral
oral
Also known as: ketamine
Beck Depression Inventory
21-question multiple-choice self-report inventory, where higher scores mean worse/more depressive symptoms
Time frame: 49 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Sao Paulo